{"id":"W4385839624","doi":"10.1038/s41591-023-02528-9","title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Genentech; Cilag; Astellas Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Adaptive Biotechnologies; Karyopharm Therapeutics; AstraZeneca España; Sanofi; Legend Biotech; Celgene; Amgen; Pfizer","keywords":"Medicine; Neutropenia; Dosing; Internal medicine; Adverse effect; Clinical endpoint; Multiple myeloma; Anemia; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Lenalidomide; Clinical trial; Surgery; Cancer; Chemotherapy; Immunotherapy; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001254242,0.0003876309,0.000877186,0.001087141,0.0001124053,0.00001217695,0.0002512403,0.0006604135,0.0007267564],"category_scores_gemma":[0.011599,0.0002430429,0.0001227824,0.002092904,0.000228896,0.00009217751,0.00009013349,0.001896454,0.0003617248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000274236,"about_ca_system_score_gemma":0.0003347934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002884013,"about_ca_topic_score_gemma":0.0004567606,"domain_scores_codex":[0.9959493,0.0002022489,0.0008383038,0.0007816217,0.001363748,0.0008648054],"domain_scores_gemma":[0.9970019,0.001247437,0.0001567887,0.0008413682,0.0001838087,0.0005687275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6869851,0.002437099,0.001927516,0.0002741806,0.0002480408,0.02114416,0.0009729745,0.000002454734,0.01050445,0.00004959271,0.1317631,0.1436912],"study_design_scores_gemma":[0.814836,0.01395557,0.04674531,0.0007670383,0.0001356466,0.0001302449,0.0004333279,0.001780738,0.001461189,0.00006706626,0.1193748,0.0003130813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735156,0.002060892,0.000004676975,0.01328733,0.001321051,0.002729662,0.0001683859,0.0003956866,0.006516757],"genre_scores_gemma":[0.9815276,0.0006908131,0.0002856482,0.0006876926,0.001453022,0.0001716763,0.00153444,0.0000671523,0.01358192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1433781,"threshold_uncertainty_score":0.9967267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04440612642337285,"score_gpt":0.3940585836265068,"score_spread":0.3496524572031339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}